Replies to post #354356 on Elite Pharmaceuticals Inc (ELTP)

[Je3232]

.055 cents per share. With all due respect, does any of what’s being said matter when the stock is so low and continues to drop

[NASDAQ2020]

Thanks for sharing your business expertise .

Have a Great Day

[jour_trader]

Organizations that do a reverse split can include the same for total authorized, so as total outstanding shares decrease the total authorized can decrease as well. This can and does happen.

Elite has zero leverage in an acquisition right now until it can consistently grow top and bottom line far greater than the company is doing today, which makes sense to pursue an up listing via R/S to stabilize the price, increase liquidity and raise funds for investments since organic growth is pretty poor, at best.

[imanjen13]

Trimpramine a drug for depression. How apropos!! Now if we come up with a drug for prostatitis, I will buy more. Adderall makes me too hyperactive.

[jgsnys]

While you state that you post as you do because you, "have the time", I post as I do because I have not the time, and certainly not the inclination to post as previously described, "voluminous posts consisting of specious theories and speculations supported by the misapplication of regurgitated, readily accessible, if not blatantly obvious "information" of a dubious character."
Once upon a time perhaps a brief window of opportunity existed whereby Elite might have become a successful company generating meaningful profits for shareholders. What was required for this to happen was first and foremost a work-ethic. As you state the need for us to see reality, I will forward the idea of competing realities, one to be realized by persons and groups who work hard thereby gaining valuable insight and experience, and one to be realized by a lackadaisical management and their supporters, both of whom possess the fruits of their daydreaming which at the end of the day show their true worth or lack thereof and nothing more.

[WeeZuhl]

Yet, without any specific data in support, it was alleged the opioid drugs Elite sold to Nostrum would have garnered $100 M in revenues. That is unmitigated bullshit and a number pulled out of thin air. But, I did the math before showing that was incorrect...At peak, the prorated aggregate market share for the owner of all four drugs sold to Nostrum in November 2019 was between $30-$50 M.

This is funny. While it is true that I pulled an opioid revenue number out of my ass, it was not $100 million, it was $50 million. And while it is true that I received a pompous correction from Math, the correction was UP UP UP not down. At the time, $50 million seemed like a fair, common sense number in a generic market worth over a billion dollars, no fancy formulas required. It seems like after multiple revised opinions from Math, we're all back to the common sense number of $50M. lol




https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157514121

While the numbers being thrown around for the cost of development are speculative, it would be informative if we can look at the alleged $50 Million market opportunity of the pain meds and the actual mathematical percentage that a prorated share of the market at peak would allow:

Percocet: 16 competitors with equal prorated market share of 6.25%/500 = 31.250 M
Norco: 11 competitors with equal prorated market share of 0.91% / 447 = 40.680 M
Ty w/code: 8 competitors with equal prorated market share of 12.5% / 45 = 5.630 M
Methadone: 10 competitors with equal prorated market share of = 10.0% / 30 = 3.00 M
Hydromorphone: 8 competitors with equal prorated market share of = 12.5% / 30 = 3.750 M

In aggregate, the prorated market share for an owner of the drugs at peak would be more than $50M, it would be = $84.310 M.

Then there is the fact that Elite’s partnerships at the time, including Glenmark, clearly did not want to sell opioids from Elite. Absent a partner to sell the drugs, there is no revenue. Relatedly, as to the fact that there has been litigation that seems unending and that companies continue to endure, cannot be easily dismissed by anyone.
...The case against Johnson & Johnson, Teva Pharmaceutical Industries Ltd, Endo International PLC and AbbVie's Allergan
...The nation's three largest drug distributors - McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc

Not sure where this idea comes from. Glenmark was selling methadone at the time Nasrat discontinued it. Two bonus points and three cheers for anyone who can identify how these companies are different than Elite: Johnson & Johnson, Teva, Endo, Allergan, McKesson Corp, AmerisourceBergen Corp and Cardinal Health. (Hint: egregious marketing and distribution practices and deep pockets.)

There are always choices that need to be made and, since Nostrum has yet to list those “valuable” opioids as being commercialized, exactly how might have Elite, without a clear partner, have sold them? I have asked for an answer to that question and it has been avoided - repeatedly!

I've answered this repeatedly but since there seems to be some misremembering going on, let's try again. First, Elite screwed their original methadone contract manufacturing partner by acquiring their own ANDA for methadone and distributing through Glenmark instead. I have no idea what the commercialization plan was for Norco and Percocet, but I don't work for Elite. These applications were not holdovers from a previous administration. These were a major part of Nasrat's strategic plan in 2016. If he didn't have a marketing plan at the time, that's on him, not me. These ANDA's were all a part of the "One New ANDA Filing Every Quarter" hype parade which was endlessly flogged at the time, similar to "Profitability" now. I don't remember hearing anything at the time about "Oh no the opioid market is decreasing" or "Oh no how will we find a partner to commercialize these drugs?"

This means the [trimipramine] market is bigger than the $2 M mentioned five years ago.

Why does it mean that? What evidence is there to say the market is increasing on this rarely-used ancient drug that is on the Beer's List of drugs that should not be prescribed for any patient over age 65?